Davide Rossi

Also affiliated with Ospedale di Santo Spirito, Università della Svizzera italiana

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 11 papers. Top paper: “Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling”.

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Nature(2023)10.1038/s41586-023-06903-x

N/A

2.5DataRank · unranked

111 citations

Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Y. Li, Cédric Rossi, Tim Flerlage +44 more

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00396-6

N/A

0.903DataRank · unranked

34 citations

Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani +19 more

Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance

Blood(2014)10.1182/blood-2014-08-592725

N/A

0.500DataRank · unranked

27 citations

Riccardo Bomben, Silvia Rasi, Michele Dal Bo, Carmela Ciardullo, Sara Monti +7 more

Phased variants improve DLBCL minimal residual disease detection at the end of therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7565

N/A

0.348DataRank · unranked

3 citations

Jacob J. Chabon, Joanne Soo, Lyron Co Ting Keh, Stefan Alig, André Schultz +15 more

rs2072135, a low‐penetrance variant for chronic lymphocytic leukaemia?

British Journal of Haematology(2013)10.1111/bjh.12366

N/A

0.276DataRank · unranked

3 citations

Helen E. Speedy, Maria Chiara Di Bernardo, Silvia Deaglio, Lidia Karabon, Irena Frydecka +10 more

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.01.522017

N/A

0DataRank · unranked

2 citations

Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas +19 more

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0068

N/A

0DataRank · unranked

17 citations

Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas +19 more

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.11.14.566994

N/A

0DataRank · unranked

4 citations

Eugenio Gaudio, Sara Napoli, Charles Herbaux, Chiara Tarantelli, Roberta Bordone +15 more

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

Leukemia(2025)10.1038/s41375-025-02662-y

N/A

0DataRank · unranked

18 citations

Thomas Chatzikonstantinou, Marina Gerousi, Richard Rosenquist, Gianluca Gaïdano, Šárka Pospı́šilová +12 more

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Haematologica(2022)10.3324/haematol.2021.279957

N/A

0DataRank · unranked

30 citations

Sara Napoli, Luciano Cascione, Giulio Sartori, Laura Barnabei, Eugenio Gaudio +20 more

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Blood Advances(2024)10.1182/bloodadvances.2023012291

N/A

0DataRank · unranked

8 citations

Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas, Chiara Tarantelli +16 more